| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
|
Matsumoto, Toshihiko
|
|
|
19 |
2 |
p. 181-190
|
article
|
| 2 |
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review
|
Crotty, Patrick
|
|
|
19 |
2 |
p. 161-173
|
article
|
| 3 |
Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study
|
Han, Gwan Hee
|
|
|
19 |
2 |
p. 251-262
|
article
|
| 4 |
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
|
Rimini, Margherita
|
|
|
19 |
2 |
p. 223-235
|
article
|
| 5 |
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
|
Ressler, Julia Maria
|
|
|
19 |
2 |
p. 263-275
|
article
|
| 6 |
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data
|
Olkus, Alexander
|
|
|
19 |
2 |
p. 213-221
|
article
|
| 7 |
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation
|
Zhao, Ruiying
|
|
|
19 |
2 |
p. 277-288
|
article
|
| 8 |
Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
|
Jin, Dian
|
|
|
19 |
2 |
p. 237-249
|
article
|
| 9 |
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A Podcast
|
Jabbour, Elias J.
|
|
|
19 |
2 |
p. 135-141
|
article
|
| 10 |
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
|
Wang, Bi-Cheng
|
|
|
19 |
2 |
p. 203-212
|
article
|
| 11 |
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
|
Batteson, Rachael
|
|
|
19 |
2 |
p. 191-201
|
article
|
| 12 |
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
|
Buchler, Tomas
|
|
|
19 |
2 |
p. 175-180
|
article
|
| 13 |
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
|
Kang, Connie
|
|
|
19 |
2 |
p. 289-296
|
article
|
| 14 |
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, Masahiro
|
|
|
19 |
2 |
p. 131-134
|
article
|
| 15 |
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review
|
Żebrowska, Urszula
|
|
|
19 |
2 |
p. 143-159
|
article
|
Journal description